











NMR Spectra



































Antibacterial activity against various Gram-positive and Gram-negative bacteria

The antibacterial activity of the compounds (**3a-d** and **7a-e**) against various bacterial strains was determined using MIC values, which represent the lowest concentration of an antimicrobial that visibly prevents bacterial growth after an overnight incubation. The bacterial strains tested included *Staphylococcus aureus* (ATCC 13709 *in vivo*, ATCC 25923, oxford, and MRSA *in vivo*), *Enterococcus faecalis* (ATCC 29212 VanS), *Enterococcus faecium* (Van A), *Streptococcus pneumoniae* (VanA, ATCC49619, PenR, and Blood effect), *Haemophilus influenzae* (ATCC 31517 MMSA), *Escherichia coli* (ATCC 25922), and *Pseudomonas aeruginosa* (ATCC 27853). MICs were determined based on CLSI methodology by a 2-fold broth dilution technique in Mueller Hinton (MH, pH 7.4 Biorad). For *S. pneumoniae* the medium was Brain Heart Infusion broth + 4% red blood cell extract. For *H. influenzae* the medium was HTM (Haemophilus Test Medium consisting of MH + 5 g/L yeast extract + hemin 15 mg/L + NAD 20 mg/L). Overnight cultures were diluted to obtain the final inoculum of 10⁵ cfu/well. Incubation was 37 °C overnight in ambient air.

CLSI- Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that grow Aerobically 7th edition Approved Standard M7-A7 Wayne PA: CLSI 2006.

souches		Phénotype	Liné	Cipro	3a	3b	3c	3d	7a	7b	7c	7e
1	<i>S. aureus</i>	Sa1	ATCC13709 <i>in vivo</i>	1	0,12	>64	>64	>64	>64	>64	>64	>64
2		Sa26	ATCC25923	2	0,5	>64	>64	>64	>64	>64	>64	>64
3		Sa26 + 10% Serum Humain	Sérum effect	2	0,5	>64	>64	>64	>64	>64	>64	>64
4		Sa26 + 50% Serum Humain	Sérum effect	2	0,5	>64	>64	>64	>64	>64	>64	>64
5		Sa4	Oxford	1	0,06	>64	>64	>64	>64	>64	>64	>64
6		Sa2	MRSA, <i>in vivo</i>	1	16	>64	>64	>64	>64	>64	>64	>64
7	<i>E. faecalis</i>	Ecalis1	ATCC29212 VanS	2	0,5	>64	>64	>64	>64	>64	>64	>64
8	<i>E. faecium</i>	Ecium1	VanA	1	16	>64	>64	>64	>64	>64	>64	>64
9	<i>S. pneumoniae</i>	Pn1	ATCC49619	0,5	1	>64	>64	>64	>64	>64	>64	>64
10		Pn9	PenR	0,5	0,5	>64	>64	>64	>64	>64	>64	>64
11		Pn9+2,5% blood	Blood effect	0,25	0,5	>64	>64	>64	>64	>64	>64	>64
12	<i>H. influenzae</i>	Hi3	ATCC 31517 MMSA	8	<=0,03	>64	>64	>64	c	c	c	c
13	<i>E. coli</i>	Ec1	ATCC25922	>32	<=0,03	>64	>64	>64	>64	>64	>64	>64
14	<i>P. aeruginosa</i>	Pa1	ATCC 27853	>32	0,25	>64	>64	>64	>64	>64	>64	>64

Cipro : Ciprofloxacin ; Lin : Linezolid

C : Contaminated

Antiviral activities (EC50, EC90) and cytotoxicity (CC50)

Compound	HRV14 - Hela Rh - 2%FCS			HCV 1b - Huh 5,2 -10%FCS		
	EC50 (μ M)	EC90 (μ M)	CC50 (μ M)	EC50 (μ M)	EC90 (μ M)	CC50 (μ M)
3a	>100	ND	>100	>50	>50	>50
3b	>100	ND	>100	>50	>50	>50
3c	>100	>100	>100	>50	>50	>50
3d	>100	>100	>100	>50	>50	>50
7a	ND	ND	68.1	>50	>50	>50
7b	>100	ND	>100	>50	>50	>50
7c	>100	>100	>100	>50	>50	>50
7e	>100	>100	>100	16,4	ND	23,6

ND: not determined